Navidea Biopharmaceuticals, Inc. NAVBQ
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -98.81% | -92.22% | -77.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -98.81% | -92.22% | -77.97% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -198.21% | -231.64% | -78.12% |
| SG&A Expenses | 5.23% | -34.49% | -43.74% | -29.39% | -12.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.54% | -17.38% | -12.08% | -6.35% | 1.69% |
| Operating Income | 16.93% | 17.38% | 10.88% | 2.93% | -9.48% |
| Income Before Tax | 53.55% | 50.58% | 4.64% | -135.68% | -12.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 53.55% | 50.58% | 4.64% | -134.14% | -12.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 301.09% | 50.58% | 4.64% | -134.14% | -12.17% |
| EBIT | 16.93% | 17.38% | 10.88% | 2.93% | -9.48% |
| EBITDA | 17.24% | 17.68% | 11.09% | 3.23% | -9.47% |
| EPS Basic | 221.80% | 54.30% | 11.15% | -211.50% | -7.95% |
| Normalized Basic EPS | 42.81% | 53.62% | 29.46% | 0.20% | -7.84% |
| EPS Diluted | 221.80% | 54.30% | 11.15% | -211.50% | -7.95% |
| Normalized Diluted EPS | 42.81% | 53.62% | 29.46% | 0.20% | -7.84% |
| Average Basic Shares Outstanding | 59.38% | 8.10% | 7.34% | 2.02% | 3.95% |
| Average Diluted Shares Outstanding | 59.38% | 8.10% | 7.34% | 2.02% | 3.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |